LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New findings from the ESMO 2026 meeting are starting to come in, and there’s plenty to talk about. So grab yourself something to drink, get comfortable, and enjoy! Stay strong and fight on! As usual, we […]
The phase 3 DASL-HiCaP trial, presented at ESMO 2026, has demonstrated improved metastasis-free survival with the addition of darolutamide to androgen deprivation therapy (ADT) and radiotherapy in patients with localised or locally advanced prostate cancer at high risk of recurrence. The randomised, placebo-controlled study enrolled 1,106 patients, who received darolutamide or placebo alongside ADT and […]
New results from a randomised substudy of the phase 3 PROTEUS trial, presented at ESMO 2026, show that adding apalutamide and androgen deprivation therapy (ADT) before and after radical prostatectomy improves outcomes compared with surgery alone in patients with high-risk localised or locally advanced prostate cancer. The substudy enrolled 408 patients, including 102 receiving perioperative […]
New phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]
Updated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]
After a median follow-up of 7.7 years, the phase 3 PEACE-1 trial confirms a lasting survival benefit from adding abiraterone and prednisone to standard treatment for men diagnosed with metastatic hormone-sensitive prostate cancer. The trial enrolled 1,173 men and tested the addition of abiraterone, prostate radiotherapy, or both to androgen deprivation therapy (ADT), with or […]
Updated phase 1 results provide further evidence of activity for JNJ-6143, previously known as HLD-0915 and also referred to as JNJ-101556143, in heavily pretreated metastatic castration-resistant prostate cancer. Following our previous coverage of its initial results and a separate phase 2 trial, the new findings add dose-specific outcomes and exploratory molecular data. JNJ-6143 is an […]
New results show preliminary antitumor activity for 225Ac-FL-020, an investigational PSMA-targeted alpha radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from ProTACT, an ongoing first-in-human phase 1 trial evaluating the safety, dosing, and preliminary efficacy of FL-020 in patients previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, unless chemotherapy […]
New results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]
New results from the phase 2 CONVERGE-01 trial, show preliminary antitumor activity of CONV01-α, an experimental PSMA-targeted alpha therapy, in patients with metastatic androgen pathway inhibitor-resistant prostate cancer (mCRPC) who had not previously received Lu-PSMA radioligand therapy. CONV01-α, also known as ²²⁵Ac-rosopatamab tetraxetan, combines the alpha-emitting isotope actinium-225 with a monoclonal antibody targeting PSMA. Unlike […]